Ozempic and Benzodiazepines: Drug Interaction Guide

Why This Interaction Gets Flagged

Drug interaction databases flag Ozempic and benzodiazepines primarily because semaglutide delays gastric emptying, which can alter the absorption profile of oral medications. The interaction is classified as low severity in most clinical decision-support tools, and no dose adjustment is required by the FDA for either medication.

Semaglutide is a GLP-1 receptor agonist that slows gastric motility as part of its pharmacologic effect. This property is one reason patients experience nausea during dose escalation. For oral co-medications, delayed gastric emptying raises a theoretical concern: if a benzodiazepine sits in the stomach longer, its peak plasma concentration (Cmax) could shift in timing or magnitude. The Ozempic prescribing information addresses this directly, noting that semaglutide "causes a delay of gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications" [1]. The key word is "potential." Clinical pharmacokinetic studies built into the drug's approval program tested this question with midazolam, a benzodiazepine used as a CYP3A4 probe substrate, and found no clinically relevant effect on total exposure [1].

This distinction between theoretical risk and measured outcome matters. Prescribers should understand the mechanism behind the flag while recognizing that the available data do not support withholding either medication.

Pharmacokinetic Data: The Midazolam Study

The FDA-approved label for Ozempic includes pharmacokinetic interaction data from a dedicated study using a single 0.5 mg oral dose of midazolam. Total systemic exposure (AUC) of midazolam was unchanged when co-administered with semaglutide at steady state, and Cmax was reduced by approximately 12% [1].

A 12% reduction in Cmax falls well within accepted bioequivalence boundaries (80%-125%) and is not considered clinically meaningful by FDA standards [2]. The slight Cmax decrease is consistent with delayed absorption rather than reduced absorption. Midazolam was chosen because it is a sensitive CYP3A4 substrate. If semaglutide inhibited or induced CYP3A4, the AUC would have changed. It did not. This confirms that semaglutide does not alter benzodiazepine metabolism through hepatic enzyme pathways.

The European Medicines Agency (EMA) assessment report for semaglutide reached the same conclusion, stating that "no dose adjustment is needed for concomitant oral medications" based on the pharmacokinetic interaction program [3]. Dr. John Buse, who served as an investigator in the SUSTAIN trial program, noted in a 2018 review that "the clinical pharmacology profile of semaglutide suggests a low propensity for drug-drug interactions mediated by CYP enzymes or drug transporters" [4].

These data apply most directly to CYP3A4-metabolized benzodiazepines like midazolam, alprazolam, and triazolam. Benzodiazepines metabolized by glucuronidation (lorazepam, oxazepam, temazepam) bypass CYP enzymes entirely, making them even less likely to interact.

Mechanism Breakdown: What Happens Physiologically

Semaglutide acts on GLP-1 receptors in the gut and brain to reduce appetite, lower blood glucose, and slow gastric emptying. The gastric emptying delay is the only mechanism through which semaglutide could plausibly affect oral benzodiazepine pharmacokinetics. No P-glycoprotein interaction, no CYP inhibition, and no protein-binding displacement have been identified [1].

When a patient takes an oral benzodiazepine like alprazolam, the drug dissolves in the stomach, passes into the duodenum, and is absorbed through the small intestinal mucosa. Semaglutide slows the transfer from stomach to duodenum. The practical result: onset of the benzodiazepine's effect may be slightly delayed, and the peak blood level may be slightly blunted. Total absorption remains equivalent.

For a patient taking alprazolam 0.5 mg for acute anxiety, this could mean the calming effect takes 15-30 minutes longer to appear. For a patient on scheduled dosing (e.g., clonazepam twice daily for a seizure disorder), the clinical impact is negligible because steady-state concentrations are maintained regardless of minor absorption delays.

Gastric emptying slowing is most pronounced during the first weeks of semaglutide therapy and during dose escalation. A scintigraphy study published in Diabetes, Obesity and Metabolism found that semaglutide 1.0 mg delayed gastric half-emptying time by approximately 30 minutes after a standardized meal compared to placebo (median 141 minutes vs. 109 minutes, P<0.01) [5]. This effect attenuated modestly over time, though it persists at steady state.

Which Benzodiazepines Carry the Lowest Risk

Not all benzodiazepines are metabolized the same way. The metabolic pathway matters because it determines whether even the theoretical CYP-related interaction is relevant. Benzodiazepines fall into two broad metabolic categories.

CYP-metabolized benzodiazepines include alprazolam (CYP3A4), midazolam (CYP3A4), triazolam (CYP3A4), and diazepam (CYP2C19 and CYP3A4). These are the agents where a CYP-mediated interaction would show up if one existed. The midazolam data from the Ozempic label confirm it does not [1].

Glucuronidation-metabolized benzodiazepines include lorazepam, oxazepam, and temazepam. These bypass the CYP system almost entirely and are conjugated directly by UDP-glucuronosyltransferases (UGTs) in the liver [6]. Since semaglutide has no demonstrated effect on UGT enzymes and the CYP pathway is irrelevant for these drugs, they represent the lowest theoretical interaction risk.

The American Geriatrics Society Beers Criteria already recommend preferring lorazepam, oxazepam, or temazepam in patients on complex medication regimens because of their simpler metabolic profiles [7]. This guidance aligns with minimizing polypharmacy risk in patients on semaglutide.

Clinical Monitoring Recommendations

Despite the low interaction severity, two clinical scenarios warrant closer monitoring. The first is semaglutide dose titration. The second is patients already experiencing significant GI side effects from semaglutide.

During the dose-escalation phase (0.25 mg for 4 weeks, then 0.5 mg, then 1.0 mg, and potentially 2.0 mg), GI symptoms peak. In the SUSTAIN-1 trial (N=388), nausea occurred in 20.3% of patients on semaglutide 0.5 mg and 23.6% on semaglutide 1.0 mg [8]. The Endocrine Society's 2024 clinical practice guideline on pharmacologic management of obesity advises clinicians to "be aware of potential interactions with oral medications due to delayed gastric emptying during the initial titration period of GLP-1 receptor agonists" [9]. Benzodiazepines taken as-needed during this window may have a slower onset. Patients should be counseled to avoid taking a second dose prematurely, assuming the first one "didn't work."

The second scenario involves sedation stacking. Semaglutide itself is not a CNS depressant. But patients on GLP-1 agonists who experience pronounced nausea, fatigue, or malaise during titration may subjectively feel more sedated when a benzodiazepine is added. The FDA label for Ozempic does not list sedation as a common adverse effect, but fatigue was reported in a small percentage of patients across the SUSTAIN program [1]. Clinicians should ask about daytime drowsiness at follow-up visits, particularly in patients taking benzodiazepines on a scheduled basis.

Dr. Caroline Apovian, a co-author of the Endocrine Society's obesity guideline, has stated that "the most practical concern with GLP-1 receptor agonists and co-administered oral drugs is not a pharmacokinetic interaction per se, but patient behavior, specifically, the temptation to re-dose a PRN medication when the first dose is delayed by slow gastric emptying" [10].

Dose Adjustment: When Is It Needed

No dose adjustment is required for semaglutide or any benzodiazepine when the two are co-administered. This is stated explicitly in the Ozempic prescribing information [1].

The FDA evaluated the pharmacokinetic interaction data from the semaglutide development program and concluded that the drug's effect on gastric emptying does not produce clinically relevant changes in exposure for tested co-medications, including midazolam, atorvastatin, digoxin, metformin, warfarin, and ethinyl estradiol/levonorgestrel [1]. If semaglutide were going to cause a problem with oral drug absorption, it would have shown up with at least one of these diverse substrates. None triggered a dose-adjustment requirement.

For prescribers who remain cautious, one practical option is to separate dosing by 1-2 hours. This approach is not mandated by the label but may ease patient anxiety about the interaction. An empty-stomach benzodiazepine dose taken 1-2 hours before or after a meal (when gastric emptying delay is most pronounced) will absorb with minimal interference.

Special Populations

Three patient groups deserve specific attention when Ozempic and benzodiazepines are co-prescribed.

Older adults (age 65+): Both drug classes require careful use in this population. Benzodiazepines increase fall risk, and GLP-1 agonists may cause dehydration through nausea and reduced oral intake. The SUSTAIN-7 trial included patients up to age 75 and did not identify age-specific interaction signals [11]. The Beers Criteria recommend avoiding benzodiazepines in older adults regardless of concurrent medications [7].

Patients with gastroparesis: Semaglutide is not recommended in patients with pre-existing severe gastroparesis (FDA label contraindication) [1]. In patients with mild gastroparesis who are already on benzodiazepines, adding semaglutide could further delay oral drug absorption. This subgroup should be monitored closely with symptom diaries.

Patients on high-dose or long-acting benzodiazepines: Clonazepam and diazepam have half-lives exceeding 20 hours. Minor absorption delays from semaglutide are irrelevant at steady state because these drugs accumulate over days, not hours. The clinical impact of delayed Tmax is essentially zero for long-acting agents.

Practical Counseling Points for Patients

Patients asking whether they can take Ozempic with their benzodiazepine should receive three clear messages.

First, the combination is considered safe based on current FDA data. No dose change is needed for either medication. Second, the benzodiazepine may take slightly longer to kick in during the first weeks of Ozempic, especially after a meal. Do not double up on doses. Third, report any unusual drowsiness, dizziness, or worsening GI symptoms to your prescriber, particularly during the Ozempic titration phase.

Written instructions should include a note that the as-needed benzodiazepine "may feel slower to work during the first 4-8 weeks of Ozempic. Wait at least 90 minutes before considering whether you need another dose, and never exceed the prescribed amount." This framing addresses the re-dosing risk without overstating the interaction severity.

Patients should also be informed that alcohol, opioids, and antihistamines pose far greater interaction risks with benzodiazepines than semaglutide does. Keeping the interaction in context prevents unnecessary medication discontinuation.